About: Gemtuzumab ozogamicin

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Gemtuzumab ozogamicin Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Recombinant humanized IgG4, kappa antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin, isolated from fermentation of a bacterium, Micromonospora echinospora ssp. calichensis. The antibody portion of Mylotarg binds specifically to the CD33 antigen, The anti-CD33 hP67.6 antibody is produced by mammalian cell suspension culture using a myeloma NS0 cell line. Gemtuzumab ozogamicin (trade name Mylotarg) was withdrawn in 2010 when a clinical trial showed the drug increased patient death and exhibited no advantages over traditional cancer therapies. (en)
http://linked.open...generalReferences	# Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res. 2001 Jun;7(6):1490-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11410481 # Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH: Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001 Jul 15;92(2):406-13. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11466696 # Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ: Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003 Sep 1;102(5):1578-82. Epub 2003 May 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12738663 (en)
http://linked.open...gy/drugbank/group	approved (en) withdrawn (en) investigational (en)
http://linked.open...ugbank/indication	For treatment of CD33-positive acute myeloid leukemia in patients 60 and over who are not candidates for other chemotherapy. (en)
http://linked.open...bank/manufacturer	Llorens Pharmaceutical
sameAs	Gemtuzumab ozogamicin Gemtuzumab ozogamicin
Title	Gemtuzumab ozogamicin (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB00056/identifier/drugbank/DB00056 http://linked.opendata.cz/resource/drugbank/drug/DB00056/identifier/national-drug-code-directory/0008-4510-01 http://linked.opendata.cz/resource/drugbank/drug/DB00056/identifier/pharmgkb/PA164749431 http://linked.opendata.cz/resource/drugbank/drug/DB00056/identifier/wikipedia/Gemtuzumab_ozogamicin
http://linked.open...mechanismOfAction	Mylotarg is directed against the CD33 antigen expressed by hematopoietic cells. Binding of the anti-CD33 antibody portion of Mylotarg with the CD33 antigen results in the formation of a complex that is internalized. Upon internalization, the calicheamicin derivative is released inside the lysosomes of the myeloid cell. The released calicheamicin derivative binds to DNA in the minor groove resulting in DNA double strand breaks and cell death. (en)
http://linked.open...drugbank/packager	Ben Venue Laboratories Inc. Liberty Pharmaceuticals
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/5585089 http://linked.opendata.cz/resource/drugbank/patent/5773001
http://linked.open...drugbank/toxicity	The most frequently reported toxicities are myelosuppression and hepatic veno-occlusive disorder. (en)
http://linked.open...y/mesh/hasConcept	http://linked.opendata.cz/resource/mesh/concept/M0483090
foaf:page	http://www.drugs.com/cdi/gemtuzumab-ozogamicin.html http://www.rxlist.com/cgi/generic2/gemtuzumab.htm
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	220578-59-6 (en)
http://linked.open...drugbank/category	(en)
http://linked.open...gbank/containedIn	Losartan potassium 50 mg tablet
http://linked.open...ank/Melting-Point	http://linked.opendata.cz/resource/drugbank/property/271B4275-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.116 as of Feb 22 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of Feb 22 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 67 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software